Deutsch
Español
India
Italiano
Français
My Account
My Account
Notifications
Overview
+ New Watchlist
Benzinga Research
Benzinga Pro
Log In
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
Get Benzinga Pro
Data & APIs
Events
Marketfy
Premarket
Boost
Advertise
Contribute
Deutsch
Español
India
Italiano
Français
Sign in
Our Services
News
Earnings
Guidance
Dividends
M&A
Buybacks
Legal
Interviews
Management
Offerings
IPOs
Insider Trades
Biotech/FDA
Politics
Government
Healthcare
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Options
Binary Options
Bonds
Futures
CME Group
Global Economics
Previews
Small-Cap
Real Estate
Cryptocurrency
Penny Stocks
Digital Securities
Volatility
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Covey Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Credit Cards
Crypto
Cannabis
Cannabis Conference
News
Earnings
Interviews
Deals
Regulations
Psychedelics
Jobs
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Options
Binary Options
Bonds
Futures
CME Group
Global Economics
Previews
Small-Cap
Real Estate
Cryptocurrency
Penny Stocks
Digital Securities
Volatility
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Covey Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Credit Cards
Crypto
Cannabis
Cannabis Conference
News
Earnings
Interviews
Deals
Regulations
Psychedelics
Jobs
Research
My Stocks
Tools
Free Benzinga Pro Trial
Calendars
Analyst Ratings Calendar
Conference Call Calendar
Dividend Calendar
Earnings Calendar
Economic Calendar
FDA Calendar
Guidance Calendar
IPO Calendar
M&A Calendar
SPAC Calendar
Stock Split Calendar
Trade Ideas
Free Stock Reports
Insider Trades
Trade Idea Feed
Analyst Ratings
Unusual Options Activity
Heatmaps
Free Newsletter
Government Trades
Short Interest
Most Shorted
Largest Increase
Largest Decrease
Calculators
Margin Calculator
Forex Profit Calculator
100x Options Profit Calculator
Recent
Markets
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
LAVA Therapeutics
(NASDAQ:LVTX)
Intraday
$2.9477
0.0977
[3.43%]
15 minutes delayed
Get Report
Watch
Perks
Buy
Compare Brokers
$2.9477
0.0977
[3.43%]
Last update: 9:33AM
Get Real Time Here
Get Report
Watch
Overview
News
Earnings
Guidance
Dividends
Analyst Ratings
Insider Trades
Short Interest
Latest News for LAVA Therapeutics Stock (NASDAQ:LVTX)
LAVA Therapeutics Stock (NASDAQ: LVTX)
Categories: All
All News
General
Contracts
Dividends
Events
FDA
M&A
Offerings
Stock Split
Media
Buybacks
Insider Trades
Earnings
Guidance
Analyst Ratings
Trading Ideas
All News
General
Contracts
Dividends
Events
FDA
M&A
Offerings
Stock Split
Media
Buybacks
Insider Trades
Earnings
Guidance
Analyst Ratings
Trading Ideas
Thursday, March 21, 2024
HC Wainwright & Co. Reiterates Buy on LAVA Therapeutics, Maintains $6 Price Target
Benzinga Newsdesk
-
Mar 21, 2024, 6:10AM
Wednesday, March 20, 2024
LAVA Therapeutics Q4 EPS $(0.24) Misses $(0.12) Estimate, Sales $353.00K Miss $6.25M Estimate
Benzinga Newsdesk
-
Mar 20, 2024, 7:13AM
Tuesday, March 05, 2024
LAVA Therapeutics shares are trading higher after the company announced a $7 million payment because Pfizer achieved a clinical milestone for PF-08046052.
Benzinga Newsdesk
-
Mar 5, 2024, 7:50AM
LAVA Therapeutics Announces Pfizer Has Achieved Clinical Development Milestone For PF-08046052, Triggering $7M Payment To LAVA
Benzinga Newsdesk
-
Mar 5, 2024, 7:31AM
Thursday, February 29, 2024
LAVA Therapeutics N.V Filed U.S. Patent Application #20240067726-A1 For "Single Domain Antibodies Targeting CD1D"
Benzinga Newsdesk
-
Feb 29, 2024, 2:24PM
Watching LAVA Therapeutics N.V.; Shares Spike Higher, Traders Circulate Speculative X Post Rumoring "$PFE Is Going To Talk About $LVTX Partnered EGFR Bispecific. This Stock Pretty Much Forgotten About."
Benzinga Newsdesk
-
Feb 29, 2024, 1:29PM
Friday, January 26, 2024
Benzinga's 'Stock Whisper' Index: 5 Stocks Investors Secretly Monitor But Don't Talk About Yet (Donald Trump Has Re-Entered The Chat)
Chris Katje
-
Jan 26, 2024, 11:50AM
Thursday, January 25, 2024
Why Humana Shares Are Trading Lower By Over 11%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Avi Kapoor
-
Jan 25, 2024, 2:52PM
Crude Oil Rises 2%; Tesla Shares Plunge After Downbeat Results
Avi Kapoor
-
Jan 25, 2024, 1:08PM
LAVA Therapeutics shares are trading higher after the company announced a clinical trial collaboration and supply agreement with Merck & Co. to evaluate LAVA-1207 in conbination with KEYTRUDA.
Benzinga Newsdesk
-
Jan 25, 2024, 10:48AM
Dow Surges Over 100 Points; US GDP Growth Tops Estimates
Avi Kapoor
-
Jan 25, 2024, 10:42AM
Why Is Cancer Focused LAVA Therapeutics Nano Cap Stock Trading Higher Today?
Vandana Singh
-
Jan 25, 2024, 10:11AM
Market-Moving News for January 25th
Benzinga Newsdesk
-
Jan 25, 2024, 8:42AM
LAVA Therapeutics Partners With Merck To Evaluate LAVA-1207 In Combination With KEYTRUDA; No Terms Disclosed
Benzinga Newsdesk
-
Jan 25, 2024, 7:10AM
Friday, November 17, 2023
HC Wainwright & Co. Reiterates Buy on LAVA Therapeutics, Maintains $6 Price Target
Benzinga Newsdesk
-
Nov 17, 2023, 6:23AM
Thursday, November 16, 2023
As Of September 30, 2023, Lava Therapeutics Had Cash, Cash Equivalents And Investments Totaling $104.6M
Benzinga Newsdesk
-
Nov 16, 2023, 7:10AM
LAVA Therapeutics Q3 EPS $(0.34) Down From $0.04 YoY
Benzinga Newsdesk
-
Nov 16, 2023, 7:09AM
Wednesday, August 23, 2023
What 5 Analyst Ratings Have To Say About LAVA Therapeutics
Benzinga Insights
-
Aug 23, 2023, 11:00AM
JMP Securities Reiterates Market Outperform on LAVA Therapeutics, Maintains $6 Price Target
Benzinga Newsdesk
-
Aug 23, 2023, 8:30AM
HC Wainwright & Co. Maintains Buy on LAVA Therapeutics, Lowers Price Target to $6
Benzinga Newsdesk
-
Aug 23, 2023, 6:17AM
Tuesday, August 22, 2023
LAVA Therapeutics Q2 EPS $(0.48) Misses $(0.47) Estimate, Sales $5.14M Beat $830.00K Estimate
Benzinga Newsdesk
-
Aug 22, 2023, 7:17AM
Thursday, June 15, 2023
JMP Securities Reiterates Market Outperform on LAVA Therapeutics, Maintains $6 Price Target
Benzinga Newsdesk
-
Jun 15, 2023, 8:25AM
Wednesday, June 14, 2023
LAVA Therapeutics Provides Updates On Clinical Programs And Extends The Cash Runway; To Prioritize Its Lead Solid Tumor Program
Benzinga Newsdesk
-
Jun 14, 2023, 9:06AM
Monday, June 12, 2023
HC Wainwright & Co. Reiterates Buy on LAVA Therapeutics, Maintains $9 Price Target
Benzinga Newsdesk
-
Jun 12, 2023, 6:11AM
Friday, June 09, 2023
JMP Securities Reiterates Market Outperform on LAVA Therapeutics, Maintains $6 Price Target
Benzinga Newsdesk
-
Jun 9, 2023, 11:54AM
Thursday, June 08, 2023
Recap: LAVA Therapeutics Q1 Earnings
Benzinga Insights
-
Jun 8, 2023, 7:15AM
LAVA Therapeutics Q1 EPS $(0.53) Misses $(0.52) Estimate, Sales $1.22M Up From $1.00M YoY
Benzinga Newsdesk
-
Jun 8, 2023, 7:05AM
Friday, June 02, 2023
Why Guidewire Software Shares Are Trading Lower By Around 13%? Here Are Other Stocks Moving In Friday's Mid-Day Session
Lisa Levin
-
Jun 2, 2023, 1:00PM
LAVA Therapeutics shares are trading higher after the company announced Janssen selected a lead gamma-delta T cell engager bispecific antibody to move toward clinical development.
Benzinga Newsdesk
-
Jun 2, 2023, 9:34AM
High-Impact Movers for June 2nd
Benzinga Newsdesk
-
Jun 2, 2023, 8:37AM
Why Lululemon Shares Are Trading Higher By 15%; Here Are 20 Stocks Moving Premarket
Lisa Levin
-
Jun 2, 2023, 7:58AM
Thursday, June 01, 2023
LAVA Therapeutics Announces Selection By Janssen Of Lead Gamma-Delta T-Cell Engager Bispecific Antibody To Move Toward Clinical Development
Happy Mohamed
-
Jun 1, 2023, 4:22PM
Thursday, April 13, 2023
HC Wainwright & Co. Reiterates Buy on LAVA Therapeutics, Maintains $9 Price Target
Benzinga Newsdesk
-
Apr 13, 2023, 6:10AM
Wednesday, March 15, 2023
Stocks That Hit 52-Week Lows On Wednesday
Benzinga Insights
-
Mar 15, 2023, 1:25PM
Friday, February 17, 2023
HC Wainwright & Co. Reiterates Buy on LAVA Therapeutics, Maintains $9 Price Target
Benzinga Newsdesk
-
Feb 17, 2023, 6:22AM
Thursday, February 16, 2023
LAVA Therapeutics Announced Initial Data from the Ongoing Phase 1/2a Clinical Trial of LAVA-1207 in Therapy Refractory mCRPC at the 2023 ASCO GU Symposium
Charles Gross
-
Feb 16, 2023, 7:13AM
Wednesday, December 14, 2022
Why Netcapital Shares Are Trading Lower By Over 33%? Here Are 49 Stocks Moving In Wednesday's Mid-Day Session
Lisa Levin
-
Dec 14, 2022, 2:04PM
Why Vallon Pharmaceuticals Shares Are Trading Higher By Over 150%; Here Are 29 Stocks Moving Premarket
Lisa Levin
-
Dec 14, 2022, 6:30AM
Wednesday, November 16, 2022
LAVA Therapeutics Q3 EPS $0.04 Up From $(0.27) YoY, Sales $15.26M Up From $2.10M YoY
Benzinga Newsdesk
-
Nov 16, 2022, 4:11PM
Tuesday, November 01, 2022
LAVA Therapeutics Announces Appointment Of Fred M. Powell As Chief Financial Officer
Benzinga Newsdesk
-
Nov 1, 2022, 7:16AM
Tuesday, October 25, 2022
Analyst Says This Small Cap Stock Might Be 'Game Changer' In Bispecific T Cell Engagers Space
Vandana Singh
-
Oct 25, 2022, 2:26PM
Benzinga's Top Ratings Upgrades, Downgrades For October 25, 2022
Benzinga Insights
-
Oct 25, 2022, 10:19AM
HC Wainwright & Co. Initiates Coverage On LAVA Therapeutics with Buy Rating, Announces Price Target of $9
Benzinga Newsdesk
-
Oct 25, 2022, 6:13AM
Friday, October 07, 2022
Lava Therapeutics To Present On-Mechanism Pharmacodynamics Data From The Phase 1/2a Clinical Trial Of Lava-051 At The Society For Immunotherapy Of Cancer 2022 Annual Meeting November 11
Benzinga Newsdesk
-
Oct 7, 2022, 11:01AM
Tuesday, September 27, 2022
Snap To Surge Around 20%? Here Are 5 Other Price Target Changes For Tuesday
Lisa Levin
-
Sep 27, 2022, 7:09AM
Why Aridis Pharmaceuticals Shares Plunged Around 30%; Here Are 81 Biggest Movers From Yesterday
Lisa Levin
-
Sep 27, 2022, 5:15AM
SVB Leerink Maintains Outperform on LAVA Therapeutics, Raises Price Target to $28
Benzinga Newsdesk
-
Sep 27, 2022, 4:27AM
Monday, September 26, 2022
Nasdaq Turns Lower; Crude Oil Drops Sharply
Lisa Levin
-
Sep 26, 2022, 2:49PM
Why LAVA Therapeutics Shares Are Trading Higher By 97%, Here Are 49 Stocks Moving In Monday's Mid-Day Session
Lisa Levin
-
Sep 26, 2022, 2:05PM
Dow Drops Over 100 Points; Crude Oil Rises Over 1%
Lisa Levin
-
Sep 26, 2022, 12:10PM
Show more